Future immunologic targets for
COVID-19
In the future, several novel immunologic targets such as tumour necrosis
factor (TNF)-α inhibitors, RLR and mTOR inhibitors, NLRP3 inflammasome
inhibitors, TLR modulators, IL-18 inhibitors and possibly mesenchymal
stem cell secretome may be tested due to their reported significance in
COVID-19 pathogenesis.
To summarise, both immunosuppression and immunomodulation could serve as
potent COVID-19 therapies. However, the benefits could only be attained
when they are administered in the appropriate disease stage / severity
(Figure 2 ) and have to consider the patients characteristics
and comorbidities to minimise adverse effects and complications.